14/09/23 -"Pharmas protecting their defensive virtues"
14/09/23 -"Pharmas protecting their defensive virtues"
In recent years, the European Pharmas’ pecking order has changed quite a lot. Investors have been dazzled by the likes of Novo Nordisk and AstraZeneca as they made some right decisions in terms of R&D priorities and/or acquisition targets. Whereas the Swiss giants were toppled from the top.
Also, the sector’s defensive virtues are being tested by some newer challenges on the regulatory front, in the form of the US Inflation Reduction Act and a stricter view on M&As, as well as upcoming patent expiries in this decade. Amid all of this, it’s worth understanding the ongoing developments to sift out the future winners.
AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.
| Corporate broking | NO |
| Trading in corporate shares | NO |
| Analyst ownership | NO |
| Advising of corporate (strategy, marketing, debt, etc) | NO |
| Research paid for by corporate | NO |
| Provision of corporate access paid for by corporate | NO |
| Link between and a banking entity | NO |
| Brokerage activity at AlphaValue | NO |